Abstracts tagged "ANCA"

Abstract Number: 741 • 2013 ACR/ARHP Annual Meeting
Granulomatosis With Polyangiitis Central Nervous System Involvement: Presentation and Management
Gonzalo De Luna^1,2, Benjamin Terrier³, Pierre Kaminsky⁴, Francois Maurier⁵, Roser Solans⁶, Raphaèle Seror⁷, Xavier Puéchal⁸, Luc Mouthon⁹ and Loic Guillevin¹⁰, ¹Medecine Interne, Cochin University Hospital, Paris, France, ²Internal Medicine, Hospital Ramon y Cajal, Madrid, Spain, ³Internal Medicine, Cochin University Hospital, Paris, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁷Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁸National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA), a small-sized–vessel vasculitis, commonly involves ear, nose & throat (ENT), lungs and kidneys, and, more rarely, the central nervous system…
Abstract Number: 2782 • 2013 ACR/ARHP Annual Meeting
Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke Unversity Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that repeat rituximab treatment may be effective in re-inducing remission in relapsing ANCA-associated vasculitis. We analyzed data from the Rituximab…
Abstract Number: 743 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)
Lindsay Lally¹, Robert Lebovics², Wei-Ti Huang³ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Otolaryngology, St. Luke's-Roosevelt Hospital Center, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: ENT involvement is the most prevalent manifestation of GPA. Rituximab (RTX) is a proven effective remission induction therapy for severe GPA with vasculitic manifestations. …
Abstract Number: 2784 • 2013 ACR/ARHP Annual Meeting
Mononeuritis Multiplex Predicts The Need For Immunosuppressive Or Immunomodulatory Drugs For Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon², Loic Guillevin⁸ and French Vasculitis Study Group (FVSG)², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Immunology and Allergology, Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland, Geneva, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA), polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without poor-prognosis factors, as defined by their 1996 Five-Factor Scores…
Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…
Abstract Number: 2785 • 2013 ACR/ARHP Annual Meeting
Urinary Inflammatory Cells Strongly Reflect the Disease Activity and Renal Function in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Minoru Sakatsume², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: The antineutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA; formerly Wegener’s), and eosinophilic granulomatosis with polyangitis (EGPA).…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…
Abstract Number: 749 • 2013 ACR/ARHP Annual Meeting
High Clinical Remission Rate With Relatively High Incidence Of Serious Infection In Newly-Onset ANCA-Associated Vasculitides In Japan – A Report From The Nationwide Prospective Cohort Study
Masayoshi Harigai¹, Ken-ei Sada², Takao Fujii³, Masahiro Yamamura⁴, Yoshihiro Arimura⁵ and Hirofumi Makino², ¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, ³Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Center for Rheumatology, Okayama Saiseikai Hospital, Okayama, Japan, ⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Clinical characteristics and antineutrophil cytoplasmic antibody (ANCA)-serology of ANCA-associated vasculitis (AAV) patients are substantially different between Western and Asian countries. We investigated effectiveness and…
Abstract Number: 750 • 2013 ACR/ARHP Annual Meeting
Maintenance Treatment In Childhood Granulomatosis With Polyangiitis
Marinka Twilt¹, Rayfel Schneider², Diane Hebert³, Elizabeth Harvey³, Ronald M. Laxer², Sharon Dell⁴, Christoph Licht³ and Susanne M. Benseler², ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is a rare but life threatening disease. Most children present with pulmonary bleeds and/or renal failure. Most treatment regimens are…
Abstract Number: 753 • 2013 ACR/ARHP Annual Meeting
Validation Of The New Histopathological Classification Of ANCA Glomerulonephritis and Its Association With Renal Outcomes In a Paediatric Population
Marinka Twilt¹, Damien Noone², Wesley Hayes², Paul Thorner³, Susanne M. Benseler⁴, Ronald M. Laxer⁴, Rulan Parekh² and Diane Hebert², ¹Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ³Pathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated glomerulonephritides (ANCA GN) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Churg-Strauss. A novel histopathologic classification for GPA…
Abstract Number: 1545 • 2012 ACR/ARHP Annual Meeting
Long-Term Follow-up of 118 Polyarteritis Nodosa and Microscopic Polyangiitis without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puechal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon⁸, Loic Guillevin⁹ and French Vasculitis Study Group FVSG¹⁰, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Internal Medicine, Hôpital Cochin, Paris, France, ³Internal medicine, Hôpital Général, Dijon, France, ⁴Internal Medicine, Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Internal Medicine, Hopital Cochim, Paris, France, ⁹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) are 2 vasculitides characterized by necrotizing inflammation of the vessel wall. They share several clinical features and…
Abstract Number: 1524 • 2012 ACR/ARHP Annual Meeting
The Use of the International Classification of Function, Disability and Health As a Conceptual Framework for Comparison of the Content of Core Outcome Instruments with the Patient Perspective in Vasculitis
Nataliya Milman¹, Peter A. Merkel², Annelies Boonen³, Lee Strunin⁴, Ryan Borg⁴ and Peter Tugwell⁵, ¹Rheumatology, Ottawa Hospital, Riverside Campus, Ottawa, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Community Health Sciences, Boston University School of Public Health, Boston, MA, ⁵Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada
Background/Purpose: The International Classification of Functioning, Disability and Health (ICF) is a general health model endorsed by the World Health Organization. It describes health along…
Abstract Number: 1531 • 2012 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis of Neutrophils Between Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Teisuke Uchida¹, Kouhei Nagai², Toshiyuki Sato², Mitsumi Arito², Nobuko Iizuka², Manae Kurokawa², Naoya Suematsu², Kazuki Okamoto², Shoichi Ozaki³ and Tomohiro Kato⁴, ¹Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine,, Kawasaki, Japan, ²Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ³Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Clinical Proteomics and Molecular Medicine, St. Mariannna University Graduate School of Medicine., Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which dysfunction of polymorphonuclear cells (PMN) is thought to…
Abstract Number: 1532 • 2012 ACR/ARHP Annual Meeting
Serum Angiopoietin-2 Level Reflects the Disease Activity and Renal Function in Antineutrophilic Cytoplasmic Antibody-Associated Vasculitis
Yoko Wada¹, Hiroe Sato¹, Takeshi Nakatsue¹, Shuichi Murakami¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Angiopoietin-2 (Ang-2) has emerged as a key mediator of endothelial cell activation. Ang-1 and Ang-2 are antagonistic ligands which bind with similar affinity to…
Abstract Number: 2564 • 2012 ACR/ARHP Annual Meeting
A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Carla Maldini¹, Matthieu Resche-Rigon², David Jayne³, Kerstin Westman⁴ and Alfred Mahr¹, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁴Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), combining granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is associated with a substantial risk of relapse or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.